Sirolimus for hard-to-treat vascular birthmarks
Treatments studied
Part of Genetic & congenital, Heart & circulation clinical trials.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a complex vascular anomaly that did not respond to usual care (medicine, surgery, and/or injections/embolization).
- Your blood counts are high enough: hemoglobin >10 g/dL, neutrophils >1500, and platelets >100,000.
- Your liver and kidney tests are within required limits (including a creatinine clearance if kidney levels are borderline).
- You are able to do study consent (and agree to follow study visits and treatment).
- If you can become pregnant, you must use effective birth control during the study; the study also excludes pregnancy and breastfeeding.
- Your overall strength is adequate (Karnofsky score >50).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called everolimus to see if it can shrink or control abnormal blood vessel growths (vascular anomalies) that have not responded to other treatments. It may offer a new option for patients aged 1 year and older.
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This trial studies whether sirolimus (Rapamune®) can reduce problems from severe arteriovenous malformations (tangled blood vessel connections). It may help shrink the abnormal vessels or improve symptoms, by testing the medicine in people with certain AVM types.
This trial studies whether taking sirolimus once a week can improve blood vessel, lymph vessel, or mixed (venolymphatic) malformations. It may help reduce symptoms and lesion size, while also monitoring safety in children and adults.
This trial tests if sirolimus can help children with a certain type of eye socket malformation. It aims to find a better treatment for children aged 1 to 18.
This trial tests whether sirolimus, a medication that may slow blood vessel changes, can help people with a condition called vertebrobasilar dolichoectasia (VBD), where a major artery in the brain becomes enlarged and twisted. If you have had symptoms or a stroke related to VBD, this study might offer a new treatment option.
Hear when a new Vascular Malformations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.